Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2022-04-28 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 4C Quarterly Cash Flow Report 4 pages 199.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly cash flow report for entities subject to Listing Rule 4.7B'. It contains detailed cash flow data for the quarter ended 31 March 2022, including receipts, payments, and net cash from operating activities. The presence of substantive financial data for a quarterly period indicates this is a comprehensive interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-04-28 English
Quarterly Activities Report 10 pages 484.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – March 2022' and contains detailed updates on clinical programs, drug development progress, trial recruitment, and business impacts for the quarter ending March 2022. It includes substantive discussion of ongoing clinical trials, drug pipeline status, and business conditions, which are typical contents of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an earnings release (which would be shorter and focused on financial highlights), nor is it a call transcript or regulatory filing. The detailed clinical and business progress updates align with the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-04-28 English
Investor Presentation 7 pages 928.9KB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation | 29 April 2022' and contains detailed information about the company's drug development pipeline, clinical trial updates, financial highlights such as share price, market cap, cash balance, and institutional ownership. It includes forward-looking statements, strategic plans, and market opportunity data. The content is structured as a presentation aimed at investors, focusing on financials, strategy, and market position rather than a formal report or regulatory filing. The length is 7356 characters, which is consistent with a detailed presentation. There is no indication that this is an annual or quarterly report, audit report, earnings release, or any other regulatory filing. Therefore, the document fits the definition of an Investor Presentation (IP).
2022-04-28 English
Pharmaxis Quarterly Investor Briefing 2 pages 126.2KB
Investor Presentation Classification · 90% confidence The document is a media release dated 26 April 2022 announcing a quarterly shareholder update and investor briefing scheduled for 29 April 2022. It invites investors and analysts to participate in a virtual briefing with a presentation and Q&A session. The content focuses on the announcement of an upcoming event rather than providing actual financial data or detailed quarterly financial statements. The document length is 4927 characters, which is relatively short and primarily serves as an announcement rather than a full report. Therefore, it fits best as an Investor Presentation (IP) announcement or a Call Transcript (CT) if it were the transcript itself. However, since this is an announcement of the briefing and not the transcript or the report itself, it is not a Call Transcript. It is also not a full Interim/Quarterly Report (IR) because it does not contain substantive financial data or analysis. Given the nature of the document as an announcement of an investor briefing with a presentation, the most appropriate classification is Investor Presentation (IP).
2022-04-25 English
R&D Showcase Presentations Webinar 2 32 pages 4.9MB
Regulatory Filings
2022-03-30 English
R&D Showcase Presentations Webinar 1 62 pages 10.3MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation | 29 March 2022' and contains detailed information about Pharmaxis' research and clinical development programs, including pipeline drugs, clinical trials, scientific rationale, and market opportunities. It includes forward-looking statements, program schedules, clinical trial designs, and scientific data presentations. The content is structured as a presentation aimed at investors, focusing on financial positioning, strategy, and product development rather than a formal regulatory filing or financial report. There is no indication that this is an annual report, earnings release, or regulatory filing. The length (15,000 characters) and detailed content support that this is the full presentation document, not just an announcement or summary. Therefore, the document fits the category of an Investor Presentation (IP).
2022-03-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.